Comparative Pharmacokinetic/Pharmacodynamic Study of Liquid Stable Glucagon Versus Lyophilized Glucagon in Type 1 Diabetes Subjects
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: There is currently no stable liquid form of glucagon commercially available. The aim of this study is to assess the speed of absorption and onset of action of G-Pump™ glucagon at 3 doses as compared to GlucaGen®, all delivered subcutaneously via an OmniPod®. Methods: Nineteen adult subjects with type 1 diabetes participated in this Phase 2, randomized, double-blind, cross-over, pharmacokinetic/pharmacodynamic study. Subjects were given 0.3, 1.2, and 2.0 µg/kg each of G-Pump glucagon and GlucaGen via an OmniPod. Results: G-Pump glucagon effectively increased blood glucose levels in a dose-dependent fashion with a glucose Cmax of 183, 200, and 210 mg/dL at doses of 0.3, 1.2, and 2.0 µg/kg, respectively ( P = ns vs GlucaGen). Mean increases in blood glucose from baseline were 29.2, 52.9, and 77.7 mg/dL for G-Pump doses of 0.3, 1.2, and 2.0 µg/kg, respectively. There were no statistically significant differences between treatments in the glucose T 50%-early or glucagon T 50%-early with one exception. The glucagon T 50%-early was greater following G-Pump treatment at the 2.0 μg/kg dose (13.9 ± 4.7 min) compared with GlucaGen treatment at the 2.0 μg/kg dose (11.0 ± 3.1 min, P = .018). There was more pain and erythema at the infusion site with G-Pump as compared to GlucaGen. No serious adverse events were reported, and no unexpected safety issues were observed. Conclusions: G-Pump glucagon is a novel, stable glucagon formulation with similar PK/PD properties as GlucaGen, but was associated with more pain and infusion site reactions as the dose increased, as compared to GlucaGen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Long-term effect of diabetes and its treatment on cognitive function
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa066397 · Cited by 646
Dagogo-Jack, S. E., Craft, S., & Cryer, P. E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116302 · Cited by 471
Mechanisms of hypoglycemia-associated autonomic failure in diabetes
Cryer, P. E. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1215228 · Cited by 433 · cited 1×
“Exercise and sleep, which by themselves already present times of high risk for hypoglycemia, may further impair the sympatho-adrenal response to hypoglycemia.(2) In a large registry of subjects with type 1 diabetes, 12% of participants had experienced a severe hypoglycemic episode resulting in a seizure or coma in the…”
BackgroundLong-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway
Skrivarhaug, T., Bangstad, H.-J., Stene, L. C., Sandvik, L., Hanssen, K. F., & Joner, G. (2006) · Diabetologia · doi:10.1007/s00125-005-0082-6 · Cited by 390
Novel Use of Glucagon in a Closed-Loop System for Prevention of Hypoglycemia in Type 1 Diabetes
Castle, J. R., Engle, J. M., Youssef, J. E., Massoud, R. G., Yuen, K. C. J., Kagan, R., & Ward, W. K. (2010) · Diabetes Care · doi:10.2337/dc09-2254 · Cited by 232
Self-citationPatterson, C. C., Dahlquist, G., Harjutsalo, V., Joner, G., Feltbower, R. G., Svensson, J., Schober, E., Gyürüs, E., Castell, C., Urbonaité, B., et al. (2007) · Diabetologia · doi:10.1007/s00125-007-0824-8 · Cited by 213
The artificial pancreas: current status and future prospects in the management of diabetes
Peyser, T., Dassau, E., Breton, M., & Skyler, J. S. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12431 · Cited by 169
Cited by
Castle, J. R., El Youssef, J., Wilson, L. M., Reddy, R., Resalat, N., Branigan, D., Ramsey, K., Leitschuh, J., Rajhbeharrysingh, U., Senf, B., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0228 · Cited by 152
Self-citationYale, J.-F., Dulude, H., Egeth, M., Piché, C. A., Lafontaine, M., Carballo, D., Margolies, R., Dissinger, E., Shames, A. R., Kaplowitz, N., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0460 · Cited by 88
Novel preparations of glucagon for the prevention and treatment of hypoglycemia
Hawkes, C. P., De Leon, D. D., & Rickels, M. R. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1216-4 · Cited by 46
Hövelmann, U., Olsen, M. B., Mouritzen, U., Lamers, D., Kronshage, B., & Heise, T. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13562 · Cited by 28
Christiansen, M. P., Cummins, M., Prestrelski, S., Close, N. C., Nguyen, A., & Junaidi, K. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002137 · Cited by 22
Self-citation
Metadata
- Authors
- Castle, J. R., Youssef, J. E., Branigan, D., Newswanger, B., Strange, P., Cummins, M., Shi, L., & Prestrelski, S.
- Venue
- Journal of Diabetes Science and Technology
- Publisher
- SAGE Publications
- Published
- 2016-07-09
- Volume
- 10
- Issue
- 5
- Pages
- 1101-1107
- ISSN
- 1932-2968 (ISSN-L)
- OpenAlex
- W2444446211
- Cited by
- 36
- References
- 7
- FWCI
- 6.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparative Pharmacokinetic/Pharmacodynamic Study of Liquid Stable Glucagon Versus Lyophilized Glucagon in Type 1 Diabetes Subjects. https://app.cochat.ai/papers/10.1177/1932296816653141
- The paper
- Castle, J. R., Youssef, J. E., Branigan, D., Newswanger, B., Strange, P., Cummins, M., Shi, L., & Prestrelski, S. (2016). Comparative Pharmacokinetic/Pharmacodynamic Study of Liquid Stable Glucagon Versus Lyophilized Glucagon in Type 1 Diabetes Subjects. Journal of Diabetes Science and Technology. https://doi.org/10.1177/1932296816653141
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.